

March 2021

S&W Seed Company (Nasdaq: SANW)



### **Forward-Looking Statements**



This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." Forward-looking statements in this release include, but are not limited to: contributions of current and future technology products to our financial performance, including the related underlying projections and assumptions; financial projections, including core revenue and revenue from tech products, and other financial components of our business model highlights; commercialization plans and our ability to leverage our industry experience and customer base to achieve our commercialization plans; pipeline product development and launch timing; potential benefits of our Double Team Sorghum, Improved Quality Alfalfa and Dhurrin-Free Sorghum products and key growth assumptions related to such products; and the execution of our strategic and commercial plans. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the related user products may be lower than anticipated; our strategic initiatives may not achieve the expected results; global pandemics and other risks are identified in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended June 30, 2020 and in other filings subsequently made by the Company with the Securities and Exchange Commission. All forward-looking st

### Significant Trait Technology Development and Commercialization Experience

#### Mark Wong, S&W Seed Company CEO

- ▶ 40+ years of experience in agriculture as a senior executive
- Successfully built, operated, and sold multiple seed technology companies to industry leaders across multiple crops, including sorghum, corn, soybeans, and vegetables.
- ► Monsanto
  - Served on the Monsanto ag board for four years, helping to write the strategy for gene sale and distribution
- ► Agrigenetics
  - ► One of the first three founding companies to transform plants in the biotech industry
  - Sold to Lubrizol Corporation for \$150 million in 1985
  - ► Agrigenetics was later sold to Mycogen seeds and thereafter to Dow Chemical
- Agracetus
  - Developed and commercialized key technologies for integration of value-added genes into soybeans and other crops
  - Eventually purchased by Monsanto for \$250 million in 1992
- Emergent genetics
  - Operated multiple international seed companies integrating technology into the company's seed lines, achieving the world's second largest market share in cotton seed
  - Sold to Monsanto for \$325 million in 2005 with a separate vegetable component of the business later sold for \$50 million to Syngenta in 2006



Mark Wong Named New CEO of S&W Seed Company on June 20, 2017

Commencing Transformation of S&W into a Leading Middle Market Agricultural Technology Company

## **Key Highlights**

#### The Ongoing Transformation of S&W

- Launch of proprietary non-GMO trait technology in FY21 anticipated to transform the operating profile of S&W into a high growth, high margin business
  - More than 50% of gross profit contribution over next decade expected to come from new tech products
  - Goal of 48% combined gross margins in FY 2031 contributing to projected \$69 million of adjusted EBITDA
- Development of three different non-GMO technologies in three different product lines (grain sorghum, alfalfa, forage sorghum) providing crop and geographic diversification
  - Double Team<sup>™</sup>, Improved Quality Alfalfa (IQ<sup>™</sup>), Dhurrin-Free Sorghum (DF<sup>™</sup>)
- Unique opportunity to leverage existing business operations, where the company has long standing relationships across many product lines, to introduce new trait technology products
  - ► 40-year operating history; leveraging large existing customer base
- Focusing on crops in which the industry has had minimal tech investment over the years providing the opportunity to become market share leader with new product introductions
  - Middle market crops expected to be key growth driver in years to come




### **Financial Vision**

# Launch of trait technology products expected to transform S&W with opportunity for significant earnings

3 Year V	ÍSION (FY24)	5 Year V	ision (FY26)	10 Year Vision (FY31)			
\$130M	Revenue Excluding Acquisitions	\$176M	Revenue Excluding Acquisitions	\$234M	Revenue Excluding Acquisitions		
\$12M	Revenue from Tech Products (Seed + Tech + License)	\$35M	Revenue from Tech Products (Seed + Tech + License)	\$70M	Revenue from Tech Products (Seed + Tech + License)		
35%	Combined Gross Profit Margins	41%	Combined Gross Profit Margins	48%	Combined Gross Profit Margins		
\$13M	Adjusted EBITDA	\$34M	Adjusted EBITDA	<b>\$69M</b>	Adjusted EBITDA		
10%	Adjusted EBITDA Margins	19%	Adjusted EBITDA Margins	30%	Adjusted EBITDA Margins		

Note that further details and assumptions can be found in the Company's presentation filed in December 2020: <u>https://swseedco.com/wp-content/uploads/2020/12/SANW-Technology-Presentation-Dec-2020.pdf</u>

# S&W Has Created a Powerful and Diversified Agricultural Platform



6

### **Core Crop Portfolio**

**Diversified middle market agricultural platform** 





S&W Seed Company (Nasdaq: SANW)

# **Seed Market Sizes**



#### ► ALFALFA

- Approximately 200 million metric tons<sup>(2)</sup>
- Global alfalfa hay crop production



- SORGHUM
- 60 million metric tons<sup>(3)</sup>
- Global sorghum crop production

\$100 million (4)

#### PASTURE SEED (Australia)

 Estimated value of cereals, alfalfa, clovers, vetch, medic in Australia

 Management estimates
 Management estimates using Reportlinker.com and Research and Markets Alfalfa Hay Global Market Trajectory and Analytics **\$70** million <sup>(5)</sup>

#### ► WHEAT (Australia)

- 24.3 million tons in Australia
- Operates under an End Point Royalty ("EPR") System

(3) USDA(4) Management's estimate using Australia Government Rural Industrial Research and Development Report



- **SUNFLOWER**
- 55 million metric tons<sup>(3)</sup>
- Global sunflower seed crop production



#### STEVIA

 Est. value of stevia as additive to food/beverage

(5) EPR market size US\$70 million, assuming 90% compliance and US\$3.19 EPR/T

(6) Management's estimate using Research and Markets Global Stevia Market by Form, By End User, By Distribution Channel, By Region, Industry Analysis and Forecast 2020-2026



### S&W's Ongoing Evolution Into A Non-GMO Seed Trait Technology Company

More than 50% of gross profit contribution expected to come from new technology products over next 10 years

#### 1980 - 2020

- Seed company with minimal trait technology integration
- Established and expanding crop portfolio
  - ► Alfalfa | Sorghum | Sunflower | Wheat | Pasture | Stevia
- ▶ Built large and diversified distribution and production capabilities
  - Products sold in more than 40 countries around the world
- ► Built and acquired R&D platform
  - Designed to drive innovation in middle market crops

### 2021 and Beyond

- ► Non-GMO Trait technology company in middle market crops
  - ▶ Commercialization expected for two traits in 2021; one trait in 2023
- Create innovation in crops that have historically been under invested
- Utilize R&D engine to create new value through advanced technology and partnerships with leading biotech companies and universities
  - Pathways include in-house development, license from third party technology developers, license from land grant universities
- Leverage large sales and field technical support staff
  - Goal of helping customers deploy new technology in crop portfolio and increase value on the farm

### Lead Novel Commercial Trait Technology Products

Three novel and proprietary products set to be commercialized





#### Double Team<sup>™</sup> Sorghum (DT<sup>™</sup>)

Double Team<sup>™</sup> Sorghum (DT<sup>™</sup>) has non-GMO tolerance to broad spectrum grass herbicide

Anticipated Launch 2021

#### Improved Quality Alfalfa (IQ<sup>™</sup>)

Improved Quality Alfalfa (IQA) is gene-edited to down-regulate lignin synthesis and improve forage digestibility in ruminants

#### Anticipated Launch 2021

#### Dhurrin-Free Sorghum (DF<sup>™</sup>)

Dhurrin Free Sorghum removes naturally toxic metabolite from stressed forage sorghum resulting in safe, worry-free grazing and hay

#### Anticipated Launch 2023

Note that further details and assumptions can be found in the Company's presentation filed in December 2020: https://swseedco.com/wp-content/uploads/2020/12/SANW-Technology-Presentation-Dec-2020.pdf

#### **Untreated Sorghum**

Field overrun by grassy weeds
 Near total yield loss due to weed competition




#### Treated With Double Team

Grassy weeds eliminated

High return on investment for trait technology

### **Proprietary Traits Development and Anticipated** Launch Timing

S&W continues to expand its pipeline of trait technology projects






### Revenue

FY ends June

- Core Revenue growth initiatives:
  - Growth in key home markets of U.S. and Australia
  - Expansion of sorghum through expanded distribution channels and introduction of new products and traits
  - Launch of sunflower program in Europe
  - Diversification away from areas with higher levels of geopolitical risk
  - Integration of recently acquired Pasture Genetics in Australia
  - **Execution** of joint venture operations in South Africa
- ► Core Revenue growth of 58% in FY 2020
  - ► 27% excluding Pasture Genetics
- ► Management expects Core Revenue growth of 30-35% in FY 2021
- \$34.2 M licensing revenue in FY 2019 from Pioneer reflects the estimated Adjusted EBITDA S&W would have recognized over the remaining 5 years of the original agreement
  - ▶ \$34.0 M of additional seed revenue to Pioneer
    - ▶ \$19.7 M in FY 2020; \$14.3 M in FY 2021




### **Selected Financials**

FY ends June

- ► Gross margin and EBITDA expansion initiatives:
  - **Growth in high-margin sorghum sales**
  - Launch of high-margin sunflower sales
  - **Expansion** of wheat end point royalty market in Australia
  - Leverage existing infrastructure through acquisition of Pasture Genetics
  - Lower COGS through strategic global production plans
  - Incremental trait and herbicide contribution from collaboration agreement with ADAMA


#### Adjusted Gross Margins



Reconciliation of Gross Margins is found included in the appendix to this presentation. FY2019 includes impact from Pioneer licensing agreement offset by inventory writedown. Reconciliation of EBITDA is included in the appendix to this presentation

### **Total Company Revenue and EBITDA Vision**

#### Significant earnings power through tech products



Revenue Ex. Tech Products Revenue from Tech Products


Adjusted EBITDA

Note that further details and assumptions can be found in the Company's presentation filed in December 2020: <u>https://swseedco.com/wp-content/uploads/2020/12/SANW-Technology-Presentation-Dec-2020.pdf</u> 2020 revenue excluding product revenue attributable to Pioneer, which the company defines as Core Revenue. Numbers may not equate due to rounding.

### **Revenue and Adjusted EBITDA Vision Bridge**

#### Business model highlights significant leverage with launch of new tech products

Fiscal Year Ends June 30



Note: 2020 revenue excluding product revenue attributable to Pioneer, which the company defines as core revenue. Numbers may not equate due to rounding. Note that further details and assumptions can be found in the Company's presentation filed in December 2020: <u>https://swseedco.com/wp-content/uploads/2020/12/SANW-Technology-Presentation-Dec-2020.pdf</u> The following is intended to provide a guide as to the potential financial opportunity for the Company. While subject to risk and uncertainty, and the Company's performance as compared to various estimates and assumptions, we believe the following provides useful insight into management's view regarding the potential growth opportunities for the Company's business, and how management intends to measure the success of its planned commercial launch of the Company's three lead trait technology products.

# **Balance Sheet** Flexibility for Growth

(\$ in Millions)	6/30/2017	6/30/18	6/30/19	6/30/20	12/31/20
Cash and cash equivalents	\$0.7	\$4.3	\$3.4	\$4.1	\$2.9
Accounts receivable, net	\$23.2	\$13.9	\$13.4	\$19.0	\$12.9
Inventory	\$31.5	\$60.4	\$71.3	\$63.9	\$72.0
Total assets	\$117.1	\$137.8	\$146.4	\$156.0	\$156.1
Short-term working capital lines	\$27.4	\$32.6	\$10.8	\$27.0	\$35.5
Pioneer note payable and earn-out	\$12.5	\$0.0	\$0.0	\$0.0	\$0.0
Other debt	\$1.4	\$13.5	\$13.3	\$16.1	\$15.4
Total shareholder's equity	\$61.2	\$81.7	\$100.0	\$81.3	\$68.5
Net working capital	\$17.9 <sup>(1)</sup>	\$37.5	\$57.7	\$35.8	\$25.4

(1) June 30, 2017 net working capital excludes Pioneer note payable and earn-out.

#### **Capital Raise Activity**

- ► In September 2018, completed \$5.0 million private placement with the Company's largest shareholder at \$3.11 per share.
- In October 2018, completed a \$22.5 million 0% coupon Series A preferred stock private placement to MFP Investors; which automatically converted to common stock at \$3.11 per share in November 2018.

#### **Banking Activity**

- \$25 million asset-based revolving credit facility with CIBC Bank USA
- AUD \$28 million revolving credit facility for the Company's Australian operations with National Australia Bank ("NAB").
- Entered into a 3-year extension with Rooster Capital LLC on its \$9.2 million real estate note with a new maturity date is November 30, 2022.

#### **Key Balance Sheet Items**

- Planted minimal acres of alfalfa production as we continue to work through our existing inventory levels.
- Inventory levels from June 2020 versus June 2019 are down by nearly \$7.4 million even after taking into account the increase in inventory from the Pasture Genetics acquisition
- Net Operating Loss Carry Forwards in excess of \$44 million



### **Shareholder Value Generation**



Launch of trait technology products expected to transform S&W into a high growth, high margin business with multiple licensing and tech trait capabilities

### **Right Markets**

Customer and market surveys indicate grower demand/adoption is expected to be strong for lead products and could help to generate annual adjusted EBITDA contribution of \$69M in FY 2031

### **Right Team**

S&W boasts one of the industry's most accomplished management teams and board of directors in bringing to market high value trait technologies

### Seed Trait Technology Management Team



#### Mark Wong Created first GMO sunflower CEO and Director Successful creation of Round

- Successful creation of Roundup Ready soybeans
- Developed Monsanto insect and herbicide gene stacks in cotton
- Developed Syngenta insect and herbicide gene stacks in cotton





Development

VP of Research and

Steve Calhoun

Mike Eade

Americas

- Technical development BXN and Roundup Ready cotton
- Development Round up Ready Flex and Bollguard II Cotton
- Development Glytol and Liberty Link cotton
- Technical development CMS Hybrid Rice
- Commercial launch of Imi Corn
- Development of Balance GT gene business
- Development of Roundup Ready corn and additional stacked traits corn and soybeans



#### Don Panter EVP, Americas

- Lead plant breeding scientist at Calgene for commercialization of GMO herbicide-resistance and insecticidal traits in cotton
- CTO for Stoneville / Emergent Genetics led integration and commercialization of GMO seed products from both inhouse and in-licensed traits including herbicide resistance traits BXN and Roundup Ready, and insecticidal Bt traits from Calgene, Monsanto and Syngenta; led out-licensing efforts to license in-house traits to outside collaborators / competitors



- David Callachor EVP, International
- 20 years of experience in the agriculture industry, including extensive international experience in hybrid seeds, traits and new technologies
- ► Limagrain Group Sales Manager for South East Asia
- National Farm Services Manager for Landmark, an Agrium Company, in Australia, where he managed all technology and service offerings in the field for the Landmark farm services business



Danielson Gardner Business Development Lead Americas

- Development of Roundup Ready Alfalfa
- Technical of development CMS Hybrid Alfalfa
- Technical of development CMS hybrid soybeans



Cameron Henley Commercial Lead MENA

VP of Sales & Marketing,

- Developed not
  - Developed novel endophytes
  - Non-GMO embryo rescue Raphanobrassica

### **Expanded Management**



Mark Wong **CEO** and Director



**Dennis** Jury SVP, International Production and Supply Chain



Jacob Kurzawa Corporate Controller



Commercial Lead Europe



Matthew Szot CFO, EVP of Finance and Administration



**Kirk Rolfs** SVP, Production and Supply Chain for the Americas



Andrea McFarlane Director of Human Resources



**David Callachor** EVP, International



**Steve Calhoun** VP of Research and Development



Danielson Gardner **Business Development** Lead Americas



**Don Panter** EVP, Americas



Mike Eade VP of Sales & Marketing -Americas



**Cameron Henley** Commercial Lead MENA

**Ernst Topitschnig** 

### **Board of Directors**



Mark Harvey Chairman of the Board



**Consuelo Madere** Former Executive Officer, Global Commerical/Operations, Monsanto Company (retired)



**Robert Straus** Portfolio Manager Wynnefield Capital





Mark Wong CEO, S&W Seed Company



Alex Matina Vice President, Investments at MFP Investors LLC



Alan Willits Former Chairman of Cargill Asia Pacific and Lead Cargill's Agriculture Supply Chain (retired)



David Fischoff Former Senior Executive R&D, Monsanto Company (retired)



**Charles Seidler** Portfolio Manager, City Financial Hedge Fund Group



# Appendix

### **Non-GAAP Financial Measures**



#### **Non-GAAP Financial Measures**

In addition to financial measures included in this presentation that are calculated in accordance with accounting principles generally accepted in the United States of America ("GAAP"), the Company has provided the following non-GAAP financial measures in this presentation: adjusted EBITDA; adjusted EBITDA margins; and Operating Expense, excluding depreciation, amortization, and stock-based compensation. S&W uses these non-GAAP financial measures internally to facilitate period-to-period comparisons and analysis of its operating performance and liquidity, and believes they are useful to investors as a supplement to GAAP measures in analyzing, trending and benchmarking the performance and value of the Company's business. However, these measures are not intended to be a substitute for those reported in accordance with GAAP. These measures may be different from non-GAAP financial measures used by other companies, even when similar terms are used to identify such measures.

Adjusted EBITDA is a non-GAAP financial measure that we define as GAAP net income (loss), adjusted to exclude non-recurring transaction costs, depreciation and amortization, non-cash stock-based compensation, foreign currency (gain) loss, change in contingent consideration liability, reduction of anticipated loss on sub-leased land, interest expense – amortization of debt discount, interest expense, and provision (benefit) for income taxes. We believe that the use of adjusted EBITDA and adjusted operating expense is useful to investors and other users of the Company's financial statements in evaluating our operating performance because it provides them with an additional tool to compare business performance across companies and across periods. We use these non-GAAP measures in conjunction with traditional GAAP operating performance measures as part of our overall assessment of our performance, for planning purposes, including the preparation of our annual operating budget, to evaluate the effectiveness of our business strategies and to communicate with our board of directors concerning our financial performance. Management does not place undue reliance on adjusted EBITDA as its only measure of operating performance. Adjusted EBITDA should not be considered as a substitute for other measures of financial performance reported in accordance with GAAP. The Company has not reconciled adjusted EBITDA to net income (loss) or adjusted operating expense because the Company has not provided assumptions for the other line items that are reconciling items, including depreciation, amortization, interest expense and stock-based compensation, among others. As these items are out of the Company's control and cannot be reasonably predicted, the Company is unable to provide such an outlook. Accordingly, reconciliation of these non-GAAP measures to their most directly comparable GAAP measures is not available without unreasonable effort.

# **Non-GAAP** Adjusted EBITDA

	Fiscal Year Ended June 30,										
	2013	2014	2015	2016	2017	2018	2019	2020			
Net Income	(\$2,516)	\$373.1	(\$3,163.1)	\$365.2	(\$11,822.0)	(\$4,725.1)	\$(9,305.2)	\$(19,674.3)			
Non-recurring cost of revenue charges	2,333.1	-	265.9	259.6	-	-	-	-			
Separation costs	-	-	-	-	674.6	-	-	-			
Restructuring charges	-	-	-	-	-	-	202.2	-			
Reserve for uncollectable sublease income	-	-	-	-	223.2	-	-				
Non-recurring acquisition related expenses	486.2	-	1,290.9	267.4	-	66.2	1,196.5	793.0			
Depreciation and amortization	694.6	1,265.7	2,179.6	3,185.1	3,325.7	3,439.3	4,128.5	5,036.5			
Impairment Charges	-	-	500.2	-	319.0	-	17,900.6	-			
Non-cash stock-based compensation	1,053.9	872.7	896.9	1,190.1	1,409.4	748.5	694.6	1,168.0			
Foreign currency (gain) loss	263.9	(51.6)	159.8	(226.5)	1.4	(12.6)	(99.5)	98.6			
Change in derivative warrant liabilities	-	-	1,396.0	(1,903.9)	(1,517.5)	(431.3)	-				
Change in estimated value of assets held for sale	-	-	-	-	-	-	1,521.9	92.9			
Reduction of anticipated loss on sublease land	-	-	-	-	-	-	(141.4)	-			
Change in contingent consideration obligations	-	-	74.0	55.1	231.6	-	-	(302.1)			
Gain on sale of marketable securities	-	-	-	(123.0)	-	-	-	-			
Loss on extinguishment of debt	-	-	-	-	-	-	-	140.6			
Loss on equity method Investment	-	-	-	294.2	144.8	-	-	-			
Interest expense – amortization of debt discount	-	52.6	2,934.2	3,899.7	1,176.0	169.0	340.8	555.0			
Interest expense – convertible debt and other	226.9	600.7	1,831.1	2,086.0	1,324.9	1,863.3	2,886.1	1,970.9			
Income tax expense (benefit)	(1,343.1)	87.1	(846.0)	(2,403.4)	7,627.7	143.0	(148.7)	386.0			
Adjusted EBITDA	\$1,199.5	\$3,200.4	\$7,519.4	\$6,945.6	\$3,543.5	\$1,260.4	\$19,176.4	\$(9 <i>,</i> 735.0)			

# FY 2018 Non-GAAP Adjustments



	co	ONSOLIDATED STATEM (unaudi		•								
		Year Ended June 30,			Year Ended June 30,							
		2018		_		2017						
	GAAP	NON-GAAP Adjustments	NON-GAAP Adjusted	_	GAAP	NON-GAAP Adjustments	NON-GAAP Adjusted					
Revenue	\$ 64,085	,510 -	\$ 64,085,510	\$	75,373,810	- 5	5 75,373,810					
Cost of revenue	49,332	.052 -	49,332,052	_	59,232,846	<u> </u>	59,232,846					
Gross profit	14,753	,458 -	14,753,458		16,140,964		16,140,964					
Operating expenses												
Selling, general and administrative expenses	10,503	,020 (66,160	) 10,436,860		11,794,026	(837,329)	10,956,697					
Research and development expenses	3,887		3,887,723		3,032,112		3,032,112					
Depreciation and amortization	3,439	.287 -	3,439,287		3,325,743		3,325,743					
Disposal of property, plant and equipment (gain) loss	(82	,980) -	(82,980)		78,538	(60,468)	18,070					
Impairment charges				_	319,001	(319,001)						
Total operating expenses	17,747	,050 (66,160	) 17,680,890	_	18,549,420	(1,216,798)	17,332,622					
Loss from operations	(2,993	,592) 66,160	(2,927,432)		(2,408,456)	1,216,798	(1,191,658)					
Other expense												
Foreign currency (gain) loss	(12	.584) -	(12,584)		1,388		1,388					
Change in derivative warrant liabilities		.300) 431,300			(1,517,500)	1,517,500						
Change in contingent consideration obligation					231,584	(231,584)						
Anticipated loss on sub-lease land					424,600	(424,600)						
Loss on equity method investment					144,841	(144,841)						
Interest expense - amortization of debt discount	169	,045 (169,045	) -		1,176,023	(1,176,023)						
Interest expense	1,863	,288 -	1,863,288	_	1,324,945	-	1,324,945					
Loss before income taxes	(4.582	.041) (196.095	) (4,778,136)		(4,194,337)	1,676,346	(2,517,991)					
Provision (benefit) for income taxes	143	.049 -	143,049		7,627,705	(8,346,088)	(718,383)					
Net loss	\$ (4,725	,090) (196,095	) \$ (4,921,185)	s	(11,822,042)	10,022,434	(1,799,608)					
Net loss per common share:												
Basic	s <u>(</u>	0.21)	\$(0.22)	\$	(0.67)	5	(0.10)					
Diluted	s <u>(</u>	0.21)	\$ (0.22)	s	(0.67)	5	6 (0.10)					
Weighted average number of common shares outstandin	g:											
Basic	22,48	1,491	22,481,491	_	17,718,057		17,718,057					
Diluted	22,48	1,491	22,481,491	_	17,718,057		17,718,057					

S&W SEED COMPANY CONSOLIDATED STATEMENTS OF OPERATIONS

## FY 2019 Non-GAAP Adjustments

SEED COMPANY

				Year Ended June 30, 2019					Year Ended June 30, 2018		
		GAAP		NON-GAAP		NON-GAAP		GAAP	NON-GAAP		NON-GAAP
Revenue		GAAP		Adjustments		Adjusted		GAAP	Adjustments		Adjusted
Product and other	s	75.507.078			s	75.507.078	s	64.085.510		s	64.085.510
Licensing	Ť	34,215,433			Ĭ	34,215,433		-			-
Total revenue		109,722,511		-		109,722,511		64,085,510	-		64,085,510
Cost of revenue											
Product and other		69,014,490		-		69,014,490		49,332,052	-		49,332,052
Total cost of revenue		69,014,490				69,014,490		49,332,052	-		49,332,052
Gross profit		40,708,021				40,708,021		14,753,458	-		14,753,458
Operating expenses											
Selling, general and administrative expenses		17,486,071		(1,398,719)		16,087,352		10,503,020	(66,160)		10,438,880
Research and development expenses		6,272,758		-		6,272,758		3,887,723	-		3,887,723
Depreciation and amortization		4,128,548		-		4,128,546		3,439,287	-		3,439,287
Gain on disposal of property, plant and equipment		(88,222)		-		(88,222)		(82,980)	-		(82,980)
Goodwill impairment charges		11,865,811		(11,885,811)		-		-	-		-
Intangible asset impairment charges		6,034,792		(6,034,792)							<u> </u>
Total operating expenses		45,701,758		(19,299,322)		26,402,434		17,747,050	(66,160)		17,680,890
Income (loss) from operations		(4,993,735)		19,299,322		14,305,587		(2,993,592)	66,160		(2,927,432)
Other expense											
Foreign currency gain		(99,467)		-		(99,467)		(12,584)	-		(12,584)
Change in derivative warrant liabilities		-		-		-		(431,300)	431,300		-
Change in estimated value of assets held for sale		1,521,855		(1,521,855)		-		-	-		-
Reduction of anticipated loss on sub-lease land		(141,373)		141,373		-		-	-		-
Interest expense - amortization of debt discount		340,847		(340,847)		-		169,045	(169,045)		-
Interest expense - convertible debt and other		2,886,077				2,886,077		1,863,288			1,863,288
Income (loss) before income taxes		(9,501,674)		21,020,651		11,518,977		(4,582,041)	(196,095)		(4,778,138)
Provision (benefit) for income taxes		(148,747)				(148,747)		143,049	-		143,049
Net income (loss)	s	(9,352,927)		21,020,651	s	11,667,724	s	(4,725,090)	(196,095)	s	(4,921,185)
Net loss attributed to noncontrolling interests		(47,685)		-		(47,685)		-	-		-
Net income (loss) attributable to S&W Seed Company	s	(9,305,242)	s	21,020,651	S	11,715,409	s	(4,725,090)	(196,095)	s	(4,921,185)
Net income (loss) per common share:											
Basic	s	(0.31)			S	0.39	S	(0.21)		s	(0.22)
Diluted	S	(0.31)			S	0.39	S	(0.21)		S	(0.22)
Weighted average number of common shares											
outstanding:											
Basic		30,102,158				30,102,158		22,481,491			22,481,491
Diluted		30,102,158				30,149,995		22,481,491			22,481,491

S&W SEED COMPANY CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

# YTD 2020 Non-GAAP Adjustments

30,102,158

33,348,263



#### S&W SEED COMPANY ITEMIZED RECONCILIATION BETWEEN GROSS PROFIT AND NON-GAAP ADJUSTED GROSS PROFIT

(UNAUDITED)

	Three Months	Ended June 30,	Years End	ed June 30,
	2020	2019	2020	2019
Gross profit	\$ 3,244,259	\$ 25,773,654	\$ 14,934,262	\$ 40,708,021
License revenue	_	(34,215,433)	_	(34,215,433)
Inventory write-downs	868,673	8,822,103	2,347,824	8,822,103
Non-GAAP Adjusted Gross Profit	\$ 4,112,932	\$ 380,324	\$ 17,282,086	\$ 15,314,691
Non-GAAP Adjusted Gross Margin	15.9%	3.0%	21.7%	20.3%

.....

Diluted

#### S&W SEED COMPANY ITEMIZED RECONCILIATION BETWEEN NET LOSS AND NON-GAAP ADJUSTED NET LOSS

(UNAUDITED)

	Three Months Ended June 30,		Years Ended June 30,			
	2020	2015	2020	2019		
Net Loss attributable to S&W Seed Company	\$ (4,802,229)	\$ (3,218,215)	\$ (19,674,324)	\$ (9,305,242)		
Non-recurring transaction costs	207,447	53,823	792,993	1,196,476		
Restructuring charges	-	202,243	-	202,243		
Goodwill impairment charges		11,865,811		11,865,811		
Intangible asset impairment charges		6,034,792		6,034,792		
Reduction of anticipated loss on sub-lease land		-		(141,373		
Change in estimated value of assets held for sale		1,521,855	92,931	1,521,855		
Change in contingent consideration	(302,139)		(302,139)			
Loss on extinguishment of debt			140,638			
Interest expense - amortization of debt discount	161,114	102,093	555,049	340,847		
Non-GAAP Adjusted Net Loss	\$ (4,735,807)	\$ 16,562,402	\$ (18,394,852)	\$ 11,715,409		
Non-GAAP Adjusted Net loss attributable to S&W Seed Company per common share:						
Basic	\$ (0.14)	\$ 0.50	\$ (0.55)	\$ 0.39		
Diluted	\$ (0.14)	\$ 0.50	\$ (0.55)	\$ 0.39		
Weighted average number of common shares outstanding:						
Basic	33,423,894	33,278,218	33,348,263	30,102,158		

33,423,894

33,278,218

#### S&W SEED COMPANY ITEMIZED RECONCILIATION BETWEEN NET INCOME (LOSS) AND NON-GAAP ADJUSTED EBITDA

		Three Months Ended				Years Ended				
		J	une 30	2019		J	une SC	2019		
Net loss attributable to S&W Seed Company	s	(4,802,229)	s	(3,218,215)	s	(19,674,324)	s	(9,305,242)		
Non-recurring transaction costs		207,447		53,823		792,993		1,196,476		
Restructuring charges		-		202,243				202,243		
Non-cash stock based compensation		373,760		160,976		1,167,951		694,610		
Depreciation and amortization		1,416,229		1,066,775		5,036,464		4,128,546		
Goodwill impairment charges		_		11,865,811		_		11,865,811		
Intangible asset impairment charges		_		6,034,792		_		6,034,792		
Foreign currency loss (gain)		31,221		(45,829)		98,620		(99,467)		
Change in estimated value of assets held for sale		-		1,521,855		92,931		1,521,855		
Change in contingent consideration		(302,139)		-		(302,139)		-		
Loss on extinguishment of debt		-		-		140,638		-		
Reduction of anticipated loss on sub-lease land		-		-		-		(141,373)		
Interest expense - amortization of debt discount		161,114		102,093		555,049		340,847		
Interest expense		588,202		828,700		1,970,882		2,886,077		
Provision for income taxes		368,744		(70,869)		385,968		(148,747)		
Non-GAAP Adjusted EBITDA	s	(1,957,651)	s	18,502,155	s	(9,734,987)	s	19,176,428		